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The completion of human and mouse genome proj-
ects has resulted in vast amounts of sequence infor-
mation and the identification of thousands of open
reading frames. For most of these genes, functional
information about their protein products remains
unknown. High throughput approaches in functional
protein analysis are required to acquire this infor-
mation, thus stimulating the development of novel
technologies.
DNA microarrays have become a well-established
research tool in modern genetics. This technique is
based on the arrangement of hundreds or thousands
of DNA or oligonucleotide sequences on a solid sup-
port, such as glass or nylon, so that each DNA spot
can be identified by its coordinates. Microarrays
have been used primarly in high throughput gene
expression profiling studies, in which the expression
of thousands of genes can be simultaneously analysed.
These studies, however, do not provide any infor-
mation about the expression of proteins. During their
biosynthesis, many proteins are post-translationally
modified by acetylation, glycosylation, phosphory-
lation or cleavage. Hence, the functional effects 
exerted by the expression of any single gene are
often multilateral. Because virtually all targets for
drug development are proteins, the development of
high throughput methodologies for their analysis is
in great demand.
A recently developed transfected-cell array (TCA)
technique is being seen as a breakthrough for high
throughput functional genomics in cell biology [1–3].
Full-length open reading frames of genes cloned in
expression vectors are printed at a high density on
a glass slide along with a lipid transfection reagent.
The microarray is subsequently covered with a layer
of cells. Cells growing on top of the DNA spots are
transfected, resulting in the expression of specific
proteins in spatially distinctive groups of cells
(Figure 1). The phenotypic effects of this ‘reverse trans-
fection’ of hundreds or thousands of gene products
can be detected using specific cell-based bioassays.
As each cell cluster expresses a particular protein
and cell clusters are spatially separated, the TCA can
be considered as a particular type of protein microar-
ray. The TCA applies eukaryotic cells, allowing for
post-translational modification (e.g. glycosylation)
of expressed proteins. Utilization of different cell
lines provides the opportunity to screen for protein
functions where cell-type-dependent post-transla-
tional modifications and protein–protein interactions
are important. Hence, investigation of protein func-
tion within the context of the living cell represents an
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RNA interference (RNAi) describes the post-transcriptional silencing of gene
expression that occurs in response to the introduction of double-stranded RNA into
cells. Application of RNAi in experimental systems has provided a great leap forward
in the elucidation of gene function. To facilitate large-scale functional genomics
studies using RNAi, several high throughput approaches have been developed based
on microarray or microwell assays. Recent establishment of large libraries of RNAi
reagents combined with a variety of detection assays further opens the door for
genome-wide screens of gene function in mammalian cells.
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attractive alternative in genome-wide functional studies,
especially for RNA interference (RNAi) approaches.
RNAi in non-mammalian cells
Two of the most common ways to investigate gene func-
tion in the context of the entire organism are gain-of-
function and loss-of-function studies using trangenic and
knockout animal technology, respectively [4]. However,
both approaches have drawbacks. One is the enormous
cost and time required for generating genetically modified
animals. Moreover, the majority of genetically modified
animals do not display a distinct change in phenotype
that would allow for its unambiguous linkage to the 
mutated gene [5]. Taking these into account, there is a
clear need for the identification of candiate genes before
endeavouring on in vivo studies.
RNAi was first described in nematodes [6] and has
quickly become the fastest expanding field in molecular
biology. The mechanism of action of RNAi is based on 
sequence-specific interactions between small interfering
RNAs (siRNAs) and mRNA molecules (Figure 2). These 
interactions trigger several enzymatic reactions that result
in the degradation of targeted mRNA molecules. 
Naturally occurring RNAi silencing is involved in the
response to viruses and transposable elements as well as
gene regulation and heterochromatin remodelling. In
plants, virus infection induces a RNAi response, which
targets viral mRNAs for degradation [7]. In Caenorhabditis
elegans, RNAi has been proposed as a protective mechanism
in the maintenance of genome stability against endogenous
transposon activity [8]. Double-stranded RNA can also 
induce methylation of endogenous sequences homologous
to viroids in infected plants [9]. Similarly, sequence ho-
mology of dsRNA to certain promoter sequences leads to
the methylation of the latter [10]. Furthermore, RNAi-
related proteins, such as piwi, are required for transgene
silencing at transcriptional and post-transcriptional levels
in Drosophila [11]. Naturally occuring small (22 nt) non-
coding RNAs known as microRNAs (miRNAs) have been
discovered in animals, including mammals, and plants.
miRNAs regulate gene expression through two modes of
action. In plants, miRNA binds complementary mRNA,
leading to its distruction through the RNAi machinery
[12]. In contrast, animal miRNAs do not require perfect
complementarity to their mRNA targets and the mechanism
of action is related to inhibition of protein synthesis [13]. It
is suggested that animal genomes contain several hundred
miRNA genes, which are largely regulated by their own
promoters [14]. There are still limited data concerning the
function of miRNAs. In C. elegans, miRNAs regulate 
expression of nuclear proteins and transcriptional factors
[15]. In Drosophila, miRNAs are involved in regulation of
FIGURE 1
Principle of reverse transfection. In the course of normal transfection (a), the cells are randomly transfected with a nucleic acid entering the cell
from the surrounding solution.The principle of the cell arrays is based on the reverse transfection process (b), whereby nucleic acid enters the
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apoptosis and fat metabolism [16]. Finally, prediction
studies towards identification of the mRNA targets for
mammalian miRNAs suggest a broad range of molecular
functions such as regulation of transcription, signal trans-
duction or protein and nucleotide binding [17].
Although discovered as a natural process, RNAi quickly
proved to be an excellent way for efficient gene silencing
[18]. Initially, silencing studies were performed in lower
eukaryotes such as C. elegans [5], or Drosophila melanogaster
[19,20] using long dsRNA. Silencing of single genes was
soon followed by high throughput approaches, mostly in
C. elegans. Taking advantage of fast and inexpensive ways
of dsRNA transfer by soaking the worms in dsRNA solution
[21] or feeding them with bacteria expressing dsRNA, many
cellular functions were analysed, including fat storage [22]
and protection against DNA mutations [23]. Because the
silencing effect of RNAi in worms is transmitted to off-
spring [24], the physiological impact of gene knockdown
can be observed throughout the development of the 
animal. Moreover, the RNAi response is systemic in char-
acter so that silencing of gene expression is observed in
tissues distally located from the place of dsRNA delivery
[25]. Several recent studies on C. elegans showed clearly
that the RNAi approach can generate dozens of pheno-
types, leading to the discovery of new genes and their
functional characterization [26,27]. For example, Kamath
et al. [26] performed RNAi analysis of 86% of the predicted
19 427 genes in the C. elegans genome and identified 1722
mutant phenotypes out of which two-thirds were not pre-
viously accociated with a phenotype. Another example of
genome-wide RNAi application comes from the studies of
Lettre et al. [27], who aimed to identify genes affecting
apoptosis in C. elegans; 21 genes stimulating apoptosis
have so far been identified. Because apoptotic pathways
are conserved, it has been suggested that many of these
genes are involved in maintenance of mammalian
genome stability, p53 activation and regulation of fertility.
The Drosophila genome has also been subjected to RNAi
analysis. Boutros et al. [28] investigated growth and viabil-
ity of Drosophila cells using a library of 19 470 dsRNAs. They
targeted 91% of predicted Drosophila genes and found 438
dsRNAs identifying essential genes. In particular, a homolog
of mammalian acute myeloid leukemia gene (AML1) was
characterised for its role in cell survival [28]. Lum et al.
used an RNAi approach in their study on signaling 
responses to the Hedgehog protein [29]. Systematic
screening of all kinases and phosphatases resulted in iden-
tification of a cell-surface protein (Dally-like protein) 
required for Hedgehog signal reception and a tumor 
suppressor casein kinase 1α.
siRNAs allow gene silencing in mammalian cells
Initially, application of RNAi in mammalian cells was
hampered by the fact that dsRNA molecules longer than
30 nt trigger an interferon response [30], which ultimately
leads to cell death. By contrast, 21 nt siRNAs do not stim-
ulate the interferon response [31,32] and can be delivered
into cells either as chemically synthesized molecules [33]
or by transfection of plasmids expressing siRNA [34]. A
wide range of mammalian genes involved in apoptosis
[35,36], the cell cycle [37,38] and signal transduction
[39,40] have been successfully knocked down using this
technique. Chemically synthesized siRNAs are easy to
transfect and a high intracellular concentration of siRNA
molecules can be achieved. High synthesis costs and a
need for silencing efficiency evaluation, however, hinder
their wide application in high throughput studies (Box I).
Gene silencing using direct transfection of siRNA is
transient and is limited by the rate of cell division. This
is because mammalian cells, unlike C. elegans, are not able
to amplify RNAi. To overcome this obstacle and to increase
the cost effectiveness of RNAi studies, vector-based systems
for siRNA delivery have been developed [34,43–45]. Cells
can be stably transfected with plasmid-expressing short
hairpin RNA (shRNA) for long-term sustainment of 
silencing. Moreover, shRNA plasmids can carry drug resist-
ance markers, making the cells suitable for selection. These
vectors contain a RNA polymerase III promoter that drives
the synthesis of shRNAs. The shRNAs are then processed
intracellularly into siRNA-like molecules [46]. Alternatively,
two tandem polymerase III promoters have been used to
FIGURE 2
RNAi silencing mechanism. Long double-stranded RNA (dsRNA) is processed to
short interfering RNA (siRNA) duplexes by the enzyme Dicer, which exhibits RNase-III-
like activity. A single strand of the siRNA is incorporated into the group of cytoplasmic
proteins to form a RNA-induced silencing complex (RISC). Activated RISC, guided by
the antisense siRNA strand, performs endonucleolytic cleavage of target mRNA.Thus
produced mRNA fragments are rapidly degraded by cytoplasmic nucleases.




































obtain sense and antisense siRNA sequences from expres-
sion constructs (convergent transcription). In addition to
plasmid-based systems, PCR-derived and enzyme-generated
siRNA expression cassettes based on single- or dual-promoter
systems can be used to efficiently suppress gene activity [47].
The silencing effect can be further prolonged using
retroviral or lentiviral RNA expression vectors [48–50].
Viral-based RNA delivery systems are chosen for the trans-
fection of primary cells [51]. Primary cells are difficult to
transfect, but they represent the most interesting target
for gene silencing because their physiology mirrors the
clinical or physiological condition of tissues or organs
from which they have been derived. Transfection by elec-
troporation has recently been proposed as an alternative
to virus-based RNAi delivery [52,53].
Finally, the development of cell- and tissue-specific
RNAi expression constructs will lead to greater versatility
and more refined applications of this technology. Although
most of the vector-based RNAi systems were used for 
silencing a limited number of genes, large siRNA expression
libraries in high throughput RNAi screens allow for the 
identification of new genes involved in different cellular
processes. Indeed, large siRNA expression libraries have
already been used in cell-based RNAi screens and have
generated important results (summarized in Table 1).
Although ∼3000 disease-modifying genes are supposed
to be present in the human genome, only ∼500 are subject
to pharmaceutical investigation [54]. Therefore, the adap-
tation of genome-wide loss-of-function screens using siRNAs
for the interrogation of complex phenotypes promises to
lead to the development of novel targets and consequently
novel therapeutic strategies. However, there are still some
limitations of this technology that have to be overcome
[55]. It has been observed that gene silencing by siRNA is
not entirely sequence specific [56,57]. False-positive 
results can arise owing to sequence-independent off-target
effects resulting from an interferon response induced by
some siRNAs but more prominently by shRNAs [58,59].
Alternatively, sequence-specific off-target responses can
be caused by crossreaction of the siRNA with related 
sequences or by interference with transcription [60]. As most
off-target effects are likely to be concentration dependent,
much effort is being put into the development of better
methods for introducing siRNA into cells to reduce both
the amount of siRNA necessary for transfection and the
cellular toxicity of transfection reagents.
False-negative results can be expected depending upon
the cell type and gene of interest, possibly owing to redun-
dancy of target genes whereby losing the function of one
gene is compensated for by products of functionally 
related genes. More frequently, however, inefficient
knockdown of the RNA of interest and/or a long half-life
of the analysed protein will hamper the identification of
important gene functions. Consequently, to obtain better
gene silencing, the prediction and validation of the best
targeted region within the gene has to be further improved.
siRNA transfection was found to be more efficient com-
pared with that of plasmid DNA expressing shRNA in
both conventional [61] and reverse transfection assays
(unpublished observations). However, it was demonstrated
at least in one study that chemically synthesized siRNA-
and vector-based-shRNA-mediated silencing could be 
obtained with comparable efficiencies in microarray-based
cell transfections [62].
Technological platforms for RNAi
At present, most large-scale RNAi-based genetic screens 
of cells in culture have used 6-, 12-, 24-, 96- or (in some
cases) even 384-well plate formats. These high through-
put assays have allowed for the selection of siRNAs that
effectively reduce mRNA and protein levels [63] but, more
importantly, they have the potential to identify key factors
that play a role in biological processes. However, until now
most of these RNAi screens have been limited to selected
subsets of genes for particular protein families.
As large libraries of shRNAs become available (see
Table 1) and companies start to offer comprehensive sets
of chemically synthesized siRNAs, there is a growing need
to take high throughput RNAi screening for mammalian
cells beyond the microwell format. In order to study 
multiple cellular processes, protein detection technologies
have to be adopted by large-scale screening platforms, with
analogy to the analysis of gene expression using DNA 
microarrays.
Reverse TCAs are a suitable platform for high throughput
cellular assays using RNAi and are, in many aspects, supe-
rior to the microwell-based approaches (see Table 2). Several
groups, including the author’s laboratory, have focused on
adapting the TCA platform for the purpose of large-scale
BOX I
Target specificity of siRNA molecules
In contrast to the long dsRNAs used in non-mammalian cells,
siRNA molecules have to be optimised to efficiently
knockdown a particular mRNA, as the effectiveness of gene
silencing depends upon the localisation of the targeted
mRNA region. Despite well-developed sequence design
algorithms, each target mRNA must be verified for an
efficient siRNA, as the silencing potential of siRNAs to
different gene regions can differ dramatically. Consequently,
genome-wide approaches based on chemically synthesized
siRNAs are very expensive. A cost-effective alternative has
recently been developed whereby siRNA molecules are
generated from long dsRNA by enzymatic processing using
purified RNase III from Escherichia coli [41,42]. Partial
digestion of dsRNA by RNase III results in production of
endoribonuclease-prepared siRNA (esiRNA) of 20–25 bp in
length, which efficiently mediates RNAi in cultured
mammalian cells.The esiRNA prepared from a single dsRNA
can target multiple sites within mRNA, thus increasing
effectiveness of gene silencing. Interestingly, shorter siRNAs
(12–15 bp) arising as a result of more extensive RNase
digestion are not able to induce an RNAi response in
mammalian cells [41].




























loss-of-function studies [62,64,65]. RNAi cell arrays are
generated by printing different siRNAs in gelatin solution
onto a modified glass surface. The array can be either
stored or immediately treated with transfection reagent and
covered with a monolayer of recipient cells. Transfection
efficiency can be monitored using fluorochrome (e.g. rho-
damine) conjugated siRNAs [64] or by cotransfection with
reporter plasmids [65].
Although conceptually similar to array-based screens in
multi-well format, the TCA method significantly reduces
the costs for high throughput loss-of-function screens,
as it requires less reagents and cells per assay. Furthermore,
the method uses technologies already well-developed for
the generation (printing robots) and analysis (array scanners)
of DNA arrays, making the technology widely accessible.
High throughput RNAi screening can be performed in
array format or using pooled siRNA libraries. In the former,
each siRNA sequence is tested individually using microwell-
or cell array-based assays. Alternatively, by pooling small
numbers of RNAi reagents, the effect of silencing mulitple
genes in one cell can be interrogated; thus a reduced num-
ber of assays has to be performed to screen the whole library.
This strategy has already been applied with vector-based
libraries. It is particularly useful in combination with 
TABLE 1 
Published large-scale RNAi libraries 







In vitro synthesized 
siRNA 
Chemically synthesized siRNA library Identification of modulators of TRAIL-
induced apoptosis 
510 510 [75] 
Chemically synthesized siRNA library Identification of negative regulators of 
the phosphoinositide 3-kinase pathway 
30 148 [76] 
EsiRNA Escherichia coli RNase III-mediated cleavage 
of dsRNA into esiRNA 
Inhibition of hepatitis C virus RNA 
replication by esiRNAs 
4  26 [41,77] 
Plasmid vectors 
Pdual A dual promoter siRNA expression system 
that allows the facile construction of siRNA 
expression libraries using a single-step PCR 
protocol 





>16 000 [78] 
REGS Restriction enzyme-generated siRNA (REGS) 
system for building unique siRNA vectors 
from cDNAs 
Silencing of Oct-3/4 and MyoD >4x104 >4x105 [79] 
ShRNAi Development of tandem-type and hairpin-
type siRNA expression vectors in piGENE 
hU6 vector to generate an siRNA expression 
library 
Identification of genes involved in 
apoptosis 
>384 >384 [80] 
PHippy A convergent opposing siRNA expression 
system using ‘HI inverted U6 promoter 
plasmid’ and PCR-amplified target 
sequences 
Silencing of PGL3 luciferase and low-
density lipoprotein receptor-related 
protein 6 
>120 120 [81] 
Expression  
Arrest™ a 
A large-scale library of RNAi-inducing shRNA 
expression vectors targeting human and 
mouse genes 
Identification of genes involved in 
proteasome function 
>15 000 >28 000 [45] 
PSUPER Collection of 50 shRNA-expressing 
constructs against de-ubiquinating human 
enzymes 
Discovery of the inhibitory effect of 
cylindromatosis tumour suppressor gene 
(CYLD) on NF-κB gene expression 
50 50 [82] 
Virus vectors 
EPRIL Enzymatic production of RNAi library (EPRIL) 
by which cDNAs are converted through a 
sequence of enzymatic treatments (PCR, 
DNase I digestion) into an RNAi library 
Isolation of gene (IP3R)-specific shRNA 
clones 
>240 >240 [42] 
SPEED SiRNA Produced by Enzymatic Engineering 
of DNA (SPEED), a retroviral shRNA library 
derived from double-stranded cDNA library 
Isolation of gene (CD45, CD53)-specific 
shRNA clones 
3x106 3x106 [83] 
Nki library 
(pRetroSuper) 
A human shRNA library in the pRetroSuper 
vector, including a barcode system for the 
rapid identification of individual siRNA 
clones associated with a specific phenotype 
Identification of new components of the 
p53 pathway 
7914 23 742 [66] 
aLibrary consists of sequence-verified shRNA expression cassettes contained within multi-functional vectors. NF-κB, nuclear factor-κB; TRAIL, tumor necrosis factor-
related apoptosis-inducing ligand. 
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selective screens, whereby loss of function leads to the 
selective survival or death of cells [66]. In the case of
pooled siRNA libraries, individual shRNA vectors can be
identified, linking the vector sequence with a unique DNA
barcode. To track the fate of the individual shRNAs in
transfected cells, barcodes are detected through hybridisa-
tion with microarrays containing oligonucleotide probes
complementary to particular barcodes [45,66].
Targeted genes are either exogenous genes, introduced
by transient or stable transfection of expression plasmids,
or endogenous genes. Targeting of exogenous genes allows
for the evaluation of the silencing capacity of different
siRNAs specific for the same target gene, and can be used
as a validation platform for functional siRNA selection
[62,67]. Functional validation of potential siRNA molecules
is still necessary despite several algorithms that exist for 
sequence design [46]. Indeed, for most algorithms, it is 
estimated that only one out of two, or even one out of
five, designed siRNAs will efficiently knockdown a target
gene [67]. When using cell arrays, large numbers of indi-
vidual siRNAs can be validated so there is no need to pool
siRNAs corresponding to the particular gene target or to
introduce sequence identifiers such as molecular barcodes.
Targeting of endogenous genes by reverse transfection
of siRNA molecules opens the possibility of parallel 
examination of many genes that regulate, or are supposed
to regulate, particular cellular processes such as apoptosis.
Gene silencing can be monitored on cell arrays by specific
fluorescent monoclonal antibodies. On the array, clusters
of cells that are negative will appear as ‘holes’ in a mono-
layer of cells that otherwise express the protein [64]. The
power of cell arrays, however, lies in the ability to analyse
downstream cellular processes that are affected by gene
silencing, either separately or in combination through
siRNA multiplexing. For example, specific antibodies can
be used to detect changes in the phosphorylation state of
cell membrane bound receptors or transcription factors
[68]. This allows for the identification of essential or novel
cell signaling molecules using genome-wide siRNA libraries,
and is of particular importance when protein tyrosine phos-
phatases [69] and kinases [70] are considered as drug 
targets for human diseases such as diabetes, cancer and
autoimmunity. Alternatively, gene silencing can induce
cellular processes such as apoptosis or changes in intercel-
lular adhesion that can be monitored by specific reagents
(e.g. Annexin V) or analysed through morphological
changes of transfected cells, respectively [1]. For the iden-
tification of genes regulating apoptosis, reverse transfection
of siRNAs can be combined with administration of prodrug,
which is a precursor converted to drug by endogenous 
activity (e.g. doxorubicin, tumour necrosis factor-α).
Several specific siRNAs efficiently sensitize cancer cells for
proapoptotic stimuli [71,72], which can help develop
novel therapeutic strategies. The possibility of combining
microwell assays with cell arrays by printing small arrays
in microwells is particularly attractive. This allows for the
simultaneous screening of compounds on multiple genes
per microwell, significantly reducing the cost and need
for manipulation of assays.
Concluding remarks
One of the possible applications using RNAi cell arrays is
the identification of transcription factors acting on target
genes. Predicted promoter regions [73] can be cloned in
vectors upstream of reporter genes, and cell lines stably
expressing the reporter construct can be subjected to
genome-wide siRNA arrays.
Similarly, cell lines derived from gene-targeted mice can
be used. Gene trapping is a high-throughput approach
that is used to introduce insertional mutations across the
genome, resulting in a collection of targeted mice. Gene
trap vectors simultaneously mutate and report the expres-
sion of the endogenous gene at the site of insertion [74] and
can therefore be used to analyse cell- and tissue-specific 
regulation of gene expression. RNAi screens using both
stable transfected cell lines (minimal promoter constructs)
and gene-trapped cell lines (endogeneous regulated 
expression) could lead to the identification of transcrip-
tion or signal transduction factors involved in gene-specific
expression activity.
Despite its short history, RNAi has already profoundly
changed the landscape of functional gene analysis. It has
greatly contributed to the characterization of gene products
and allowed cost-effective large-scale loss-of-function stud-
ies on a genome-wide level. Combination of microarray
TABLE 2 
Comparison of microwell plate- and microarray-based RNAi 
platforms 
96-microwell plate Cell array 
Advantages  
Possibility of flow-cytometric analysis Low reagent consumption (reagents 
necessary for single-well transfection 
sufficient for up to 500 reverse 
transfections) 
Possibility of transfection by 
electroporation (primary cells) 
Cost-effective system for silencing with 
chemically synthesized siRNAs 
Suitable for non-adhesive cells Higher throughput (up to 10 000 
samples) in a single experiment 
Cost-effective for smaller sample sets Possibility of long-term storage of printed 
microarrays 
Well-established functional assays for 
microwell plate format 
Suitable for analysis on a single cell level 
(e.g. subcellular protein distribution) 
Disadvantages  
Higher consumption of reagents Limited to adhesive cells 
Higher number of cells per sample 
required 
Not suitable for screening of protein 
targets with a long turn-over (over  
72 h) 
High throughput experiments require 
expensive automation of dispensing 
processes 
Transfection limited to lipid-based 
approaches 
Detection of the collective signal from 
many cells 
Low number of targeted cells per sample 
hampers advanced statistical analysis 




























technology and cellular biology methods should in the
future provide additional impetus toward the development
of robust RNAi-based screening methods and consequently
toward efficient drug target selection and evaluation.
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